nach oben

Erschienen in:

Open Access 01.12.2024 | Research

Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA

verfasst von: Yizi Gong, Chanjuan Shen, Ting Meng, Wei Lin, Xueling Hu, Rong Tang, Qi Xiong, Joshua D. Ooi, Peter J. Eggenhuizen, Jinbiao Chen, Ya-Ou Zhou, Hui Luo, Jia Xu, Ning Liu, Ping Xiao, Xiangcheng Xiao, Yong Zhong

Erschienen in: Clinical and Experimental Medicine | Ausgabe 1/2024

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) patients with dual positivity for proteinase 3-ANCA (PR3-ANCA) and myeloperoxidase-ANCA (MPO-ANCA) are uncommon. We aimed to investigate these idiopathic double-positive AAV patients’ clinical features, histological characteristics, and prognosis. We reviewed all the electronic medical records of patients diagnosed with AAV to obtain clinical data and renal histological information from January 2010 to December 2020 in a large center in China. Patients were assigned to the MPO-AAV group or PR3-AAV group or idiopathic double-positive AAV group by ANCA specificity. We explored features of idiopathic double-positive AAV. Of the 340 patients who fulfilled the study inclusion criteria, 159 (46.76%) were female, with a mean age of 58.41 years at the time of AAV diagnosis. Similar to MPO-AAV, idiopathic double-positive AAV patients were older and had more severe anemia, lower Birmingham Vasculitis Activity Score (BVAS) and C-reactive protein (CRP) levels, less ear, nose, and throat (ENT) involvement, higher initial serum creatinine and a lower estimated glomerular filtration rate (eGFR) when compared with PR3-AAV (P < 0.05). The proportion of normal glomeruli of idiopathic double-positive AAV was the lowest among the three groups (P < 0.05). The idiopathic double-positive AAV patients had the worst remission rate (58.8%) among the three groups (P < 0.05). The relapse rate of double-positive AAV (40.0%) was comparable with PR3-AAV (44.8%) (P > 0.05). Although there was a trend toward a higher relapse rate of idiopathic double-positive AAV (40.0%) compared with MPO-AAV (23.5%), this did not reach statistical significance (P > 0.05). The proportion of patients who progressed to ESRD was 47.1% and 44.4% in the idiopathic double-positive AAV group and MPO-AAV group respectively, without statistical significance. Long-term patient survival also varied among the three groups (P < 0.05). Idiopathic double-positive AAV is a rare clinical entity with hybrid features of MPO-AAV and PR3-AAV. MPO-AAV is the “dominant” phenotype in idiopathic double-positive AAV.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) is a group of autoimmune disorders characterized by inflammation and/or necrosis of small- to medium-sized blood vessels, endothelial injury, and tissue damage [1]. Microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic GPA (EGPA) are three main types of AAV according to the 2012 Chapel Hill Consensus Conference [2]. As a hallmark of AAV, proteinase 3-ANCA (PR3-ANCA) or myeloperoxidase-ANCA (MPO-ANCA) can be detected. Although the classification of the clinical phenotype has been commonly used for AAV since the 1990 s, evidence supporting the classification based on the ANCA subtype has been growing [3‐8].

Whether AAV patients who were double positive for PR3-ANCA and MPO-ANCA were distinguishable from single positivity AAV for PR3-ANCA or MPO-ANCA remains elusive. Hence, we aimed to explore the clinical features, histological characteristics, and prognosis of the rare idiopathic double-seropositive AAV patients in this study.

Methods

Study population

This retrospective analysis included patients diagnosed with AAV between January 2010 and December 2020 in Xiangya Hospital, China, according to the 2012 Chapel Hill Consensus Conference [2]. The classification criteria we used in this study are the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for AAV [9‐11] and the Watt’s Algorithm for classifying AAV [12]. Standard indirect immunofluorescence assay (IFA) (Euroimmun, Lübeck, Germany) and direct enzyme-linked immunosorbent assay (ELISA) (Inova Diagnostics, San Diego, USA) were applied to detect the presence of ANCA. AAV patients who tested positive for both MPO-ANCA and PR3-ANCA were assigned to the double-positive AAV group. Before diagnosis, the tests were repeated at least once to avoid the diagnosis of double-positive on occasion. The tests were also repeated during the follow-up. The ANCA testing results of ELISA were paired with IFA. The cut-off levels for MPO-ANCA and PR3-ANCA titers were both 20 U/ml. Patients were assigned to the MPO-AAV group, PR3-AAV group, or idiopathic double-positive AAV group by ANCA specificity at the diagnosis, hereafter MPO-AAV, PR3-AAV, and idiopathic double-positive AAV. The exclusion criteria were as follows: (1) EGPA or secondary vasculitis, e.g., infective endocarditis; (2) the coexistence of other autoimmune disease or nephropathy; (3) patients positive for anti-glomerular basement membrane (GBM); (4) pregnancy, or previous malignancy; (5) activated hepatitis B virus, hepatitis C virus, or human immunodeficiency virus infection; (6) drug-induced AAV.

The last time we followed up with our patients was March 30, 2022. And the median time of follow-up was 27.33 months (range 0.13–134.10 months).

Data retrieval

We reviewed all the eligible patients’ electronic medical records to obtain data and information, which contain baseline clinical characteristics, laboratory test data, systems involved, comorbidities, renal histological information, and therapeutic regimen. We used the Birmingham Vasculitis Activity Score (BVAS; version 3) to estimate disease activity [13]. Systems involvement was determined by biopsy or using previously described criteria [14, 15]. The original pathology records of kidney biopsy were collected and evaluated by two professional pathologists. The percentage of glomeruli with different features according to the presence of global sclerosis, crescents, and necrosis was calculated. Renal biopsies were classified into focal, crescentic, mixed, or sclerotic subgroups based on the Berden classification [16]. Glomerular features like fibrinoid necrosis, Bowman’s capsule rupture, granulomatous lesions, and thrombotic microangiopathy were also recorded. Arteriolar lesions were listed as fibrinoid necrosis. A semi-quantitative score was used to describe interstitial infiltrates and tubulointerstitial lesions, namely mild (score of 1) for < 25% renal tubulointerstitial involvement, moderate (score of 2) for 25–50% renal tubulointerstitial involvement, and severe (score of 3) for > 50% renal tubulointerstitial involvement [17]. To evaluate the intensity of C3, C4, C1q, IgA, IgG, and IgM in the renal biopsies, we scored them under an immunofluorescence microscope after staining with fluorescein-conjugated (FITC) antisera specific for C3, C4, C1q, IgA, IgG, IgM. They were listed as scale 0 for negative ( − ), scale 1 for trace ( ±) and mild (1 +), scale 2 for moderate (+ +), and scale 3 for strong (+ + +)[18]. The prognosis of renal risk was according to the renal risk score published by Brix et al. [19].

Treatment

Management of AAV according to the KDIGO guidelines and EULAR/ERA-EDTA recommendations was administered to patients in induction remission and maintenance remission [20, 21]. For induction remission, patients received glucocorticoids together with cyclophosphamide or rituximab. Cyclophosphamide was administered intravenously 500–750 mg/m² per month and the dosage was adjusted according to the count of leukocytes to maintain it above 4 × 10⁹/L. The rituximab dose was 375 mg/m² of body surface area, once a week or 1000 mg twice a month for four infusions. Furthermore, plasma exchange and/or intravenous methylprednisolone pulses were also administered to some patients. During maintenance remission, the patients received azathioprine (1.5–2 mg/kg/d) or mycophenolate mofetil (250-1000 mg/d bid) in combination with low-dose glucocorticoids. The dosage of azathioprine or mycophenolate mofetil was adjusted by age, eGFR, side effects, and level of white blood cells.

Definitions

ESRD was defined as a requirement for hemodialysis or peritoneal dialysis for over 3 months or kidney transplantation [22]. Remission was defined as the absence of typical signs, symptoms, or other features of active AAV with or without immunosuppressive therapy [23, 24]. Relapse was defined as the recurrence of active AAV after a period of remission [23, 24]. We define the time from treatment to the development of ESRD as renal survival and the time from treatment to death as patient survival. The estimated glomerular filtration rate (eGFR) was estimated by the CKD-EPI creatinine equation [25]. Disease duration was defined as the time from symptoms to diagnosis. Follow-up duration was defined as the time of initial treatment to the occurrence of death or the deadline of follow-up.

Statistical analysis

We used SPSS Statistics v.26 (IBM Corp, Armonk, NY, USA) and GraphPad Prism v.9 (GraphPad Software, La Jolla, CA, USA) to analyze data. Shapiro–Wilk test was used to test normally distributed variables. Continuous data were presented as mean (± SD) or median (interquartile range, IQR). Categorical variables were expressed as frequency and percentage. Continuous data were compared by using ANOVA with post hoc LSD test or Kruskal–Wallis test. For the comparison of categorical variables, the χ2 test or Fisher’s exact test was applied. Kaplan–Meier curves depicted survival distribution and log-rank tests verified unadjusted survival differences. A two-sided P value < 0.05 was considered statistically significant.

Results

Demographics and subject characteristics

A total of 401 patients were included in this study between January 2010 and December 2020 in Xiangya Hospital (Fig. 1). 14 patients were excluded due to diagnosis of anti-GBM disease (1 out of 14 were dual-positive for MPO-ANCA and PR3-ANCA). 11 patients were excluded because of other autoimmune diseases or nephropathy (2 out of 11 were dual-positive for MPO-ANCA and PR3-ANCA, one was diagnosed with Sjögren's syndrome and the other one was diagnosed with membranous nephropathy). 7 patients were excluded due to previous malignancy and infections (2 out of 7 were dual-positive for MPO-ANCA and PR3-ANCA, one had esophageal malignant tumors before and the other one was combined with infective endocarditis). And 29 patients were lost during follow-up (3 out of 29 were dual-positive for MPO-ANCA and PR3-ANCA, these three patients were associated with propylthiouracil (PTU)). Finally, 340 patients were enrolled in our study.

Of the 340 patients who fulfilled the study inclusion criteria, 159 (46.76%) were female, with a mean age of 58.41 years at the time of AAV diagnosis. Among these 340 patients, 286 (84.1%) patients were in the MPO-AAV group, 37 (10.9%) patients in the PR3-AAV group, and 17 (5.0%) patients in the idiopathic double-positive group. Among the 17 idiopathic double-positive AAV patients, 16 patients were positive for p-ANCA while 1 patient was positive for c-ANCA. The average titer for MPO-ANCA of the 17 idiopathic double-positive AAV patients was 84.00 ± 39.26 U/ml. The median titer for PR3-ANCA of them was 38.87 U/ml, ranging from 30.15 to 190.49 U/ml. The clinical characteristics of the 3 groups are shown in Table 1. The age of idiopathic double-positive AAV patients (57.59 ± 14.97) was similar to MPO-AAV patients (60.55 ± 13.99) but were older than PR3-AAV patients (43.35 ± 16.66) (P < 0.05). No significant difference in sex distribution among the 3 groups was found in our study. Among 17 idiopathic double-positive patients, 2 (11.8%) were diagnosed with GPA, and 15 (88.2%) were diagnosed with MPA. We found no significant difference in the duration of disease when comparing idiopathic double-positive AAV with the other two groups.

Table 1

Baseline clinical characteristics and outcomes

	MPO-AAV (n = 286)	PR3-AAV (n = 37)	Double-positive AAV (n = 17)	P value
Age, year (mean, SD)	60.55 ± 13.99	43.35 ± 16.66^a	57.59 ± 14.97^b	< 0.0001
Female (%)	135 (47.2%)	13 (35.1%)	11 (64.7%)	0.121
•Vasculitis type, n (%)
MPA	245 (85.7%)	5 (13.5%)	15 (88.2%)	< 0.0001
GPA	41 (14.3%)	32 (86.5%)	2 (11.8%)	< 0.0001
Duration of disease, d (median, IQR)	58 (31, 95)	89 (38, 327)^a	74 (23, 150)	0.020
White blood cells, 10⁹/L (mean, SD)	9.37 ± 4.79	12.49 ± 7.09^a	6.88 ± 3.00^{a, b}	0.001
Neutrophil, 10⁹/L (mean, SD)	7.46 ± 4.50	9.22 ± 6.76	6.46 ± 4.97	0.227
Lymphocyte, 10⁹/L (mean, SD)	1.14 ± 0.63	1.17 ± 0.63	0.90 ± 0.46	0.129
Hemoglobin, g/L (mean, SD)	82.68 ± 20.04	95.49 ± 23.47^a	74.15 ± 40.10^b	0.010
Platelet, 10⁹/L (mean, SD)	246.25 ± 108.04	330.39 ± 170.52^a	183.71 ± 80.06^{a, b}	0.001
Serum albumin, g/L (mean, SD)	30.66 ± 6.04	38.05 ± 17.22^a	35.46 ± 11.12^a	0.016
Serum globulin, g/L (mean, SD)	31.06 ± 6.62	31.93 ± 6.96	33.13 ± 5.24	0.365
Proteinuria, g/24 h (median, IQR)	1.08 (0.65, 2.05)	0.83 (0.41, 1.91)	1.83 (0.94, 2.97)	0.435
Hematuria, n (%)	201 (70.3%)	27 (73.0%)	11 (64.7%)	0.826
Initial serum creatinine, μmol/L (median, IQR)	329.5 (161.775, 562)	104 (64, 215.2)^a	473.4 (167, 659)^b	< 0.0001
Initial eGFR, ml/min/1.73 m (median, IQR)	14 (7.3, 32.9025)	72.81 (35.495, 111.19)^a	7.42 (6.82, 30.78)^b	< 0.0001
ESR, mm/h (median, IQR)	67.5 (39.25, 106.75)	80 (49.25, 120)	47 (29.5, 93.50)	0.229
CRP, mg/L (median, IQR)	22.30 (5.11, 76.75)	74.80 (21.8, 128.50)^a	8.94 (4.28, 67.75)^b	< 0.0001
Serum C3, mg/L (mean, SD)	766.68 ± 220.80	902.93 ± 406.77	792.00 ± 156.79	0.215
Serum C4, mg/L (mean, SD)	238.25 ± 103.78	226.04 ± 131.80	234.94 ± 65.32	0.838
IgA, mg/L (mean, SD)	2441.47 ± 1182.56	2858.32 ± 1055.82	2255.31 ± 1052.27	0.151
IgG, g/L (mean, SD)	14.05 ± 4.61	14.65 ± 5.60	14.85 ± 5.44	0.677
IgM, mg/L (mean, SD)	1079.08 ± 664.70	1189.80 ± 721.96	968.25 ± 484.53	0.566
BVAS (mean, SD)	17.45 ± 5.94	19.73 ± 5.48^a	14.71 ± 6.03^b	0.011
No. of systems involved	3 (2, 3)	4 (3, 5)^a	2 (2, 3)^b	< 0.0001
Renal involvement, n (%)	271 (94.8%)	32 (86.5%)	16 (94.1%)	0.121
ENT involvement, n (%)	23 (8.0%)	12 (32.4%)^a	1 (5.9%)^b	< 0.0001
Lung involvement, n (%)	193 (67.5%)	27 (73.0%)	9 (52.9%)	0.343
•Comorbidities
Hypertensive diseases, n (%)	111 (38.8%)	5 (13.5%)^a	3 (17.6%)	0.003
Lung diseases, n (%)	105 (36.7%)	13 (35.1%)	4 (23.5%)	0.543
Type 2 diabetes mellitus, n (%)	24 (8.4%)	3 (8.1%)	1 (5.9%)	1.000
Coronary heart disease, n (%)	21 (7.3%)	3 (8.1%)	1 (5.9%)	0.905
Median follow-up time, months (median, IQR)	26.3 (12.11, 41.56)	39.37 (18.03, 65.67)^a	33.33 (7.63, 63.18)	< 0.0001
Requirement for RRT at presentation, n (%)	79 (27.6%)	3 (8.1%)^a	4 (23.5%)	0.036
•Outcomes
Remission, n (%)	238 (83.2%)	29 (78.4%)	10 (58.8%)^a	0.037
Relapse, n (%)	56 (23.5%)	13 (44.8%)^a	4 (40.0%)	0.020
ESRD, n (%)	127 (44.4%)	8 (21.6%)^a	8 (47.1%)	0.028
Death, n (%)	90 (31.5%)	5 (13.5%)^a	2 (11.8%)	0.021

MPO-AAV Myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated vasculitis, PR3-AAV proteinase 3–anti-neutrophil cytoplasmic antibody-associated vasculitis, Double-positive AAV double-positive anti-neutrophil cytoplasmic antibody-associated vasculitis, MPA microscopic polyangiitis, GPA granulomatosis with polyangiitis, EGPA eosinophilic GPA, eGFR estimated glomerular filtration rate, ESR erythrocyte sedimentation rate, CRP C-reactive protein, BVAS birmingham vasculitis activity score, ENT ear nose and throat, RRT renal replacement therapy, CYC cyclophosphamide, RTX rituximab, ESRD end-stage renal disease

^aP < 0.05 vs. MPO-AAV

^bP < 0.05 vs. PR3-AAV

Idiopathic double-positive AAV patients had the lowest level of white blood cells among the three groups (6.88 ± 3.00) (P < 0.05). While the number of neutrophils and lymphocytes did not significantly differ from each group. The degree of anemia in idiopathic double-positive AAV (74.15 ± 40.10), reflected by the level of hemoglobin, was comparable to MPO-AAV (82.68 ± 20.04) and more severe than PR3-AAV (95.49 ± 23.47). The idiopathic double-positive AAV patients had the lowest level of platelets (183.71 ± 80.06) and the PR3-AAV patients had the highest level of platelets (330.39 ± 170.52) (P < 0.05). As for renal involvement, idiopathic double-positive AAV and MPO-AAV demonstrated more severe kidney damage than PR3-AAV patients, which was reflected by higher initial serum creatinine(Dp-AAV vs. MPO-AAV vs. PR3-AAV) (473.4 (167, 659) μmol/L vs. 329.5 (161.775, 562) μmol/L vs. 104 (64, 215.2) μmol/L) (P < 0.05) and lower initial eGFR (Dp-AAV vs. MPO-AAV vs. PR3-AAV) (7.42 (6.82, 30.78) mL/(min·1.73 m²) vs. 14 (7.3, 32.9025) mL/(min·1.73 m²) vs. 72.81 (35.495, 111.19) mL/(min·1.73 m²)) (P < 0.05). CRP levels for idiopathic double-positive AAV patients (8.94 (4.28, 67.75)) (median, IQR) was similar to MPO-AAV (22.30 (5.11, 76.75)) (median, IQR) (P > 0.05), which was much lower than the PR3-AAV group (74.80 (21.8, 128.50)) (median, IQR) (P < 0.05). Idiopathic double-positive AAV also had lower BVAS (14.71 ± 6.03) than PR3-AAV (19.73 ± 5.48) (P < 0.05), which was similar to MPO-AAV (17.45 ± 5.94) (P > 0.05). Furthermore, with regard to ENT involvement, similar to MPO-AAV patients (8.0%), idiopathic double-positive AAV (5.9%) had less ENT involvement than PR3-AAV (32.4%) (P < 0.05). Finally, the percentage of patients required for RRT at the commencement of treatment was 23.5% in the idiopathic double-positive AAV group.

Renal histopathology

Seventy-four (25.9%) patients in the MPO-AAV group, 10 (27.0%) patients in the PR3-AAV group, and 7 (41.2%) patients in the idiopathic double-positive AAV group underwent renal biopsy. The pathological characteristics of the cohort are described in Table 2.

Table 2

The pathological characteristics

	MPO-AAV	PR3-AAV	double-positive AAV	P value
•No. of kidney biopsies, n (%)	74 (25.9%)	10 (27.0%)	7 (41.2%)	0.383
•Berden classification
Focal, n (%)	11 (14.9%)	3 (30.0%)	1 (14.3%)	0.413
Crescentic, n (%)	22 (29.7%)	4 (40.0%)	3 (42.9%)
Mixed, n (%)	20 (27.0%)	1 (10.0%)	3 (42.9%)
Sclerotic, n (%)	21 (28.4%)	2 (20.0%)	0 (0%)
•Glomerular lesions
The proportion of normal glomeruli, % (median, IQR)	20 (0, 42)	43 (30, 85)	17 (14, 27)	0.021
The proportion of sclerotic glomeruli, % (median, IQR)	28 (13, 50)	6 (0, 48)	31 (0, 36)	0.170
The proportion of crescentic glomeruli, % (median, IQR)	42 (18, 60)	28 (0, 52)	44 (36, 50)	0.308
The proportion of cellular crescents, % (median, IQR)	0 (0, 11)	0 (0, 32)	5 (0, 50)	0.538
The proportion of cellular-fibrous crescents, % (median, IQR)	14 (0, 39)	0 (0, 32)	6 (0, 33)	0.346
Fibrinoid necrosis, n (%)	31 (41.9%)	1 (10.0%)	2 (28.6%)	0.141
Bowman’s capsule rupture, n (%)	22 (29.7%)	2 (20.0%)	4 (57.1%)	0.262
Thrombotic microangiopathy, n (%)	8 (10.8%)	0 (0%)	0 (0%)	0.788
•Interstitial infiltrates (n, 0/1/2/3)	0/32/34/8	0/7/3/0	0/2/3/2	0.263
•Tubulointerstitial lesions (n, 0/1/2/3)	0/26/34/14	0/7/3/0	0/3/2/2	0.205
•Arteriolar lesions
Vascular fibrinoid necrosis, n (%)	3 (4.1%)	0 (0%)	1 (14.3%)	0.327
•Immunofluorescence pattern, n (%)
C3 Number of negative	50 (67.6%)	6 (60.0%)	6 (85.7%)	0.683
Number of 1 +	10 (13.5%)	1 (10.0%)	1 (14.3%)
Number of ≥ 2 +	14 (18.9%)	3 (30.0%)	0 (0%)
C4 Number of negative	62 (83.8%)	10 (100.0%)	7 (100.0%)	1.000
Number of 1 +	6 (8.1%)	0 (0%)	0 (0%)
Number of ≥ 2 +	6 (8.1%)	0 (0%)	0 (0%)
C1q Number of negative	67 (90.5%)	6 (60.0%)	7 (100.0%)	0.076
Number of 1 +	3 (4.1%)	2 (20.0%)	0 (0%)
Number of ≥ 2 +	4 (5.4%)	2 (20.0%)	0 (0%)
IgA Number of negative	55 (74.3%)	7 (70.0%)	4 (57.1%)	0.365
Number of 1 +	14 (18.9%)	1 (10.0%)	2 (28.6%)
Number of ≥ 2 +	5 (6.8%)	2 (20.0%)	1 (14.3%)
IgG Number of negative	51 (68.9%)	7 (70.0%)	6 (85.7%)	0.909
Number of 1 +	10 (13.5%)	1 (10.0%)	1 (14.3%)
Number of ≥ 2 +	13 (17.6%)	2 (20.0%)	0 (0%)
IgM Number of negative	38 (51.4%)	3 (30.0%)	3 (42.9%)	0.599
Number of 1 +	11 (14.9%)	1 (10.0%)	1 (14.3%)
Number of ≥ 2 +	25 (33.8%)	6 (60.0%)	3 (42.9%)
•Brix renal risk score, n (%)
Low-risk group	11 (14.9%)	7 (70.0%)^a	0 (0.0%)^b	0.002
Medium-risk group	30 (40.5%)	2 (20.0%)	4 (57.1%)
High-risk group	33 (44.6%)	1 (10.0%)	3 (42.9%)

^aP < 0.05 vs. MPO-AAV

^bP < 0.05 vs. PR3-AAV

In the idiopathic double-positive group, 1 out of 7 (14.3%) was classified as focal, 3 out of 7 (42.9%) were classified as crescentic, and 3 out of 7 (42.9%) were classified as mixed. There were no significant differences in the Berden classification among the three groups. The percentage of normal glomeruli tended to be lower in idiopathic double-positive AAV compared with the other two groups (P < 0.05), though the differences were not statistically significant when comparing every two groups in all three groups. The features of the glomerulus, including fibrinoid necrosis, Bowman’s capsule rupture, granulomatous lesions, and thrombotic microangiopathy, did not differ from each other in this cohort. Nevertheless, we noticed a relatively high level of Bowman’s capsule rupture of idiopathic double-positive AAV (57.1%). No significant differences in scores of interstitial infiltrates and tubulointerstitial lesions were found among the three groups. Neither were there significant differences in arteriolar fibrinoid necrosis and the intensity of deposits (C3, C4, C1q, IgA, IgG, and IgM) under an immunofluorescence microscope.

According to Brix’s Renal Risk Score (RRS), 33 out of 74 (44.6%) patients in the MPO-AAV group were classified into the high-risk group, while 7 out of 10 (70.0%) patients in the PR3-AAV group into the low-risk group. In the idiopathic double-positive group, 4 out of 7 (57.1%) patients were classified into the medium-risk group, and the percentage of the low-risk group was zero. The differences between the three groups were significant (P < 0.05). Both the proportions of the low-risk group in MPO-AAV patients and idiopathic double-positive AAV patients were lower than PR3-AAV (P < 0.05).

Outcomes and survival analysis

Patient outcomes are shown in Table 1. The idiopathic double-positive AAV patients had the worst remission rate (58.8%) among the three groups (P < 0.05). The relapse rate of double-positive AAV (40.0%) was comparable with PR3-AAV (44.8%) (P > 0.05). Although there was a trend toward a higher relapse rate of idiopathic double-positive AAV (40.0%) compared with MPO-AAV (23.5%), this did not reach statistical significance (P > 0.05). The proportion of patients in idiopathic double-positive AAV who progressed to ESRD was 47.1% and that of MPO-AAV was 44.4%, where there was no statistical significance. The proportion of patients who progressed to ESRD in the PR3-AAV group (21.6%) was lower than that in the idiopathic double-positive AAV group (P < 0.05) without statistical significance. The idiopathic double-positive AAV group tended to have the lowest death rate among the three groups.

As shown in Fig. 2, idiopathic double-positive AAV tended to have worse long-term renal survival among the three groups, although there was no statistical difference in unadjusted analysis (P = 0.374). Long-term patient survival also varied among the three groups (P = 0.010) (Fig. 3). However, no significant difference in long-term patient survival was found when comparing idiopathic double-positive AAV with either MPO-AAV (P = 0.062) or PR3-AAV (P = 0.993).

Discussion

To the best of our knowledge, our cohort included the largest number of double-positive AAV patients to compare outcomes of idiopathic double-positive AAV and single-positive AAV so far. The results of our study shed light on features of double-positive AAV. Demonstrating a hybrid disease phenotype, idiopathic double-positive AAV patients exhibited the propensity for renal deterioration of MPO-AAV and also exhibited the long-term risk of relapse tendency of PR3-AAV.

There was no evidence-based data about the incidence and prevalence of idiopathic double-positive AAV. Pearce, et al. mentioned 9 patients both PR3- and MPO-ANCA positive among a total of 1217 AAV patients [26]. Kim, et al. retrospectively summarized the characteristics of 8 biopsy-proven vasculitis patients with dual MPO- and PR3-ANCA positivity [27]. Chou et al. described the outcomes of 15 patients positive for both PR3- and MPO-ANCA. They found that 3 of 15 were finally diagnosed with AAV and presented with MPO-predominance [28]. Previous case reports about double-positive AAV were related to drug-induced AAV, membranous nephropathy, Henoch-Schonlein purpura, infective endocarditis, Moyamoya, mixed connective tissue disease and systemic lupus erythematosus [29]. We cautiously ruled out all possible secondary causes before our analysis.

As found in this study, idiopathic double-positive AAV exhibited composite characteristics of MPO-AAV and PR3-AAV. The main clinical phenotype of double-positive AAV was more like MPO-AAV. To elaborate on this, idiopathic double-positive AAV patients took features of MPO-AAV such as older age distribution, more severe anemia, lower BVAS, and CRP level, less ENT involvement, and more severe renal dysfunction, which was presented with higher initial serum creatinine and lower initial eGFR. Also, the prognosis of Brix’s RRS showed that the renal prognosis of PR3-AAV was better than that of MPO-AAV and idiopathic double-positive AAV. The similarity of age distribution and more severe renal dysfunction in idiopathic double-positive AAV is compatible with the study of Kim et al. [27]. Moreover, comparable with MPO-AAV, a majority of idiopathic double-positive AAV patients were diagnosed with MPA. There were 75% of double-positive AAV patients diagnosed with MPA in Kim's study [27]. We assumed that MPO-ANCA might play an important role in idiopathic double-positive AAV. In our cohort, there were more idiopathic double-positive patients being positive for p-ANCA and MPO-ANCA titers were higher compared with PR3-ANCA titers in these patients.

The relatively lower proportion of remission of idiopathic double-positive AAV cannot be ignored. Remission rates at 12 weeks and 1 year were also reported to be relatively lower in Kim's study [27]. Interestingly, idiopathic double-positive AAV patients have the lowest level of platelets in this study. Our group has demonstrated that treatment resistance was negatively associated with platelet levels in MPO-AAV previously [30]. Since idiopathic double-positive AAV showed a major MPO-AAV phenotype, we assume that the lower remission rate of idiopathic double-positive AAV had a possible correlation with its lower platelet counts.

Furthermore, it is noteworthy that idiopathic double-positive AAV patients had more probability of relapse, which was similar to PR3-AAV. The higher rate of relapse in PR3-AAV compared with MPO-AAV was verified in many other studies before [31‐33]. Owing to the possibility of treatment resistance and risk of relapse, idiopathic double-positive AAV patients should be very carefully monitored.

Notably, idiopathic double-positive AAV had a worse renal prognosis. It was revealed that double-positive AAV had a relatively high rate of a requirement for RRT at presentation and a high proportion of patients progressed into ESRD. In addition, it appeared that idiopathic double-positive AAV had less normal glomeruli among the three groups. Since previous studies have suggested that the percentage of normal glomeruli is a reliable and independent predictor for renal outcome [19, 34], it is conceivable that idiopathic double-positive AAV patients have a high incidence of ESRD in our cohort. Also, the high ratio of Bowman’s capsule rupture in the idiopathic double-positive AAV group should not be ignored. Extra-capillary proliferation can occur via Bowman’s capsule rupture leading to infiltration of inflammatory cells and affecting the constitution of crescents [35]. Anqun Chen et al. observed that unimpaired Bowman's capsule could prevent CD8⁺ T cells from accessing podocytes. The podocyte can be destroyed by CD8⁺ T cells after Bowman's capsule rupture [36]. The higher initial serum creatinine, lower initial eGFR and relatively worse renal survival also suggest that idiopathic double-positive AAV patients might present with a “more deteriorative” renal function than PR3-AAV. No studies have analyzed the renal survival of idiopathic double-positive AAV before. Despite no significant differences in the death rate when comparing idiopathic double-positive AAV with MPO-AAV or PR3-AAV, there was no denying that the overall patient survival of idiopathic double-positive AAV was poor.

The mechanism for the production of dual-specificity ANCA remains elusive. NETS comprising extracellular DNA and histones, and neutrophil proteins such as myeloperoxidase, neutrophil elastase, or calgranulin can be released to the extracellular space after a particular process of neutrophil death called NETosis [37]. NETs not only have immunogenicity in vasculitis but also damage glomerular endothelial cells, podocytes, and parietal endothelial cells [38, 39]. Autoreactive T cells might recognize MPO and PR3 from NETs generated by neutrophils through antigen-presenting cells and then induce B cells to produce anti-MPO and anti-PR3 antibodies [40, 41]. Through animal experiments, we assumed that the production of MPO-ANCA and PR3-ANCA was related to DNA particles taken up by monocyte-derived dendritic cells (DCs) [42]. Moreover, MPO-ANCA and PR3-ANCA might not activate neutrophils in the same way [5]. In vitro,MPO-ANCA and PR3-ANCA cause neutrophils to be activated and go through an oxidative burst and degranulate [43]. PR3-ANCA can stimulate neutrophils more potently [44], and the sialylation level of PR3-ANCA correlated with the extent of the oxidative burst [45]. It needs further study to explore whether there exit synergistic effects of activating neutrophils between MPO-ANCA and PR3-ANCA in AAV or not. Further studies focusing on the disease pathogenesis of idiopathic double-positive AAV are needed. Double-positive AAV patients turned to be single-positive or negative for MPO-ANCA and PR3-ANCA during follow-up. It was reported that ANCA was considered to be a well-recognized diagnostic biomarker and the persistence of ANCA is related to the occurrence of relapse in the future [46, 47]. However, it was controversial to use ANCA titers to predict disease activities and/or guide therapy [3]. The usefulness of ANCA for follow-up was inconclusive. For these reasons, we highlighted the role of ANCA during the course of diagnosis rather than the ANCA persistence during follow-up.

There were certain limitations in our research. Firstly, the number of idiopathic double-positive AAV patients and the cases of patients who underwent kidney biopsy are relatively small, the firmness of the conclusion was circumscribed by which. Secondly, there was selection bias owing to our data coming from one single Chinese provincial center. Thus, further larger sample-sized research of idiopathic double-positive AAV conducted in multiple centers is required.

In summary, idiopathic double-positive AAV is a rare clinical entity with hybrid features of MPO-AAV and PR3-AAV. MPO-AAV is the “dominant” phenotype in idiopathic double-positive AAV. Except for the high risk of relapse like PR3-AAV, idiopathic double-positive AAV patients also experience unfavorable long-term renal prognoses like MPO-AAV.

Acknowledgements

The authors thank all the staff of the Department of Nephrology and the nursing staff for their dedicated assistance in patient follow-up data collection.

Declarations

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethics approval

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of the Xiangya Hospital of Central South University (approval number 201711836). The patients/participants provided their written informed consent to participate in this study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

Jetzt testen ¹

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt bestellen und 100 € sparen!

Jetzt testen ²

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Jetzt bestellen und 100 € sparen!

Jetzt testen ³

Kitching AR, Anders H-J, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020;6(1):71. https://doi.org/10.1038/s41572-020-0204-y. (PubMed PMID: 32855422).CrossRefPubMed

Jennette J, Falk R, Bacon P, Basu N, Cid M, Ferrario F, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11. https://doi.org/10.1002/art.37715. (PubMed PMID: 23045170).CrossRefPubMed

Cohen Tervaert JW, Damoiseaux J. Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up? Clin Rev Allergy Immunol. 2012;43(3):211–9. https://doi.org/10.1007/s12016-012-8320-4. (PubMed PMID: 22669754).CrossRefPubMed

Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DRW, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–23. https://doi.org/10.1056/NEJMoa1108735. (PubMed PMID: 22808956).CrossRefPubMedPubMedCentral

Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis—clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016;12(10):570–9. https://doi.org/10.1038/nrrheum.2016.123. (PubMed PMID: 27464484).CrossRefPubMed

Berglin E, Mohammad AJ, Dahlqvist J, Johansson L, Eriksson C, Sjöwall J, et al. Anti-neutrophil cytoplasmic antibodies predate symptom onset of ANCA-associated vasculitis. A case-control study J Autoimmun. 2021;117: 102579. https://doi.org/10.1016/j.jaut.2020.102579. (PubMed PMID: 33340843).CrossRefPubMed

Unizony S, Villarreal M, Miloslavsky E, Lu N, Merkel P, Spiera R, et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75(6):1166–9. https://doi.org/10.1136/annrheumdis-2015-208073. (PubMed PMID: 26621483).CrossRefPubMed

Windpessl M, Bettac EL, Gauckler P, Shin JI, Geetha D, Kronbichler A. ANCA status or clinical phenotype—what counts more? Curr Rheumatol Rep. 2021;23(6):37. https://doi.org/10.1007/s11926-021-01002-0. (PubMed PMID: 33909191).CrossRefPubMedPubMedCentral

Grayson P, Ponte C, Suppiah R, Robson J, Craven A, Judge A, et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):309–14. https://doi.org/10.1136/annrheumdis-2021-221794. (PubMed PMID: 35110334).CrossRefPubMed

10.

Robson J, Grayson P, Ponte C, Suppiah R, Craven A, Judge A, et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):315–20. https://doi.org/10.1136/annrheumdis-2021-221795. (PubMed PMID: 35110333).CrossRefPubMed

11.

Suppiah R, Robson J, Grayson P, Ponte C, Craven A, Khalid S, et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81(3):321–6 (PubMed PMID: 35110332).CrossRefPubMed

12.

Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222–7 (PubMed PMID: 16901958).CrossRefPubMed

13.

Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827–32. https://doi.org/10.1136/ard.2008.101279. (PubMed PMID: 19054820).CrossRefPubMed

14.

Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7(1):33–9 (PubMed PMID: 8808107).CrossRefPubMed

15.

Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7(1):23–32 (PubMed PMID: 8808106).CrossRefPubMed

16.

Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628–36. https://doi.org/10.1681/ASN.2010050477. (PubMed PMID: 20616173).CrossRefPubMed

17.

Chen Y, Bao H, Liu Z, Liu X, Gao E, Zeng C, et al. Risk factors for renal survival in Chinese patients with myeloperoxidase-ANCA-associated GN. Clin J Am Soc Nephrol. 2017;12(3):417–25. https://doi.org/10.2215/CJN.06200616. (PubMed PMID: 28148558).CrossRefPubMedPubMedCentral

18.

Lin W, Shen C, Zhong Y, Ooi JD, Eggenhuizen P, Zhou Y-O, et al. Glomerular immune deposition in MPO-ANCA associated glomerulonephritis is associated with poor renal survival. Front Immunol. 2021;12: 625672. https://doi.org/10.3389/fimmu.2021.625672. (PubMed PMID: 33841408).CrossRefPubMedPubMedCentral

19.

Brix SR, Noriega M, Tennstedt P, Vettorazzi E, Busch M, Nitschke M, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177–88. https://doi.org/10.1016/j.kint.2018.07.020. (PubMed PMID: 30385041).CrossRefPubMed

20.

KDIGO. Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021. https://doi.org/10.1016/j.kint.2021.05.021. (PubMed PMID: 34556256).CrossRef

21.

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–94. https://doi.org/10.1136/annrheumdis-2016-209133. (PubMed PMID: 27338776).CrossRefPubMed

22.

Huang L, Shen C, Zhong Y, Ooi JD, Zhou Y-O, Chen J-B, et al. The association of neutrophil-to-lymphocyte ratio with all-cause mortality in Chinese patients with MPO-ANCA associated vasculitis. Clin Exp Med. 2020;20(3):401–8. https://doi.org/10.1007/s10238-020-00629-0. (PubMed PMID: 32318926).CrossRefPubMed

23.

Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023. https://doi.org/10.1136/ard-2022-223764. (PubMed PMID: 36927642).CrossRef

24.

Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605–17 (PubMed PMID: 17170053).CrossRefPubMed

25.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12 (PubMed PMID: 19414839).CrossRefPubMedPubMedCentral

26.

Pearce FA, Craven A, Merkel PA, Luqmani RA, Watts RA. Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2017;56(11):1962–9. https://doi.org/10.1093/rheumatology/kex293. (PubMed PMID: 28968886).CrossRefPubMed

27.

Kim SM, Choi S-Y, Kim SY, Kim J. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study. Rheumatol Int. 2019;39(11):1919–26. https://doi.org/10.1007/s00296-019-04447-w. (PubMed PMID: 31552433).CrossRefPubMed

28.

Chou J, Randall K, Gatenby P. Clinical outcomes of patients with dual positivity for proteinase 3 and myeloperoxidase specific antineutrophil cytoplasmic antibodies. Int Med J. 2014;44:7 (PubMed PMID: WOS:000342722800020).

29.

Elias John E, Roy S, Sundar Raj Mani S, Joseph Eapen J, Mishra U, Varughese S. Rare case of renal limited dual anti-neutrophil cytoplasmic antibody-associated vasculitis: double trouble! Eur J Case Rep Intern Med. 2022;9(5):003365. https://doi.org/10.1290/2022_003365. (PubMed PMID: 35774735).CrossRefPubMedPubMedCentral

30.

Huang L, Shen C, Zhong Y, Ooi JD, Zhou Y-O, Chen J-B, et al. Risk factors for treatment resistance and relapse of Chinese patients with MPO-ANCA-associated vasculitis. Clin Exp Med. 2020;20(2):199–206. https://doi.org/10.1007/s10238-020-00614-7. (PubMed PMID: 32078076).CrossRefPubMed

31.

de Joode AAE, Sanders JSF, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol. 2013;8(10):1709–17. https://doi.org/10.2215/CJN.01020113. (PubMed PMID: 23846462).CrossRefPubMedPubMedCentral

32.

Bantis K, Stangou MJ, Kalpakidis S, Nikolaidou C, Lioulios G, Mitsoglou Z, et al. Different types of ANCA determine different clinical phenotypes and outcome in ANCA-associated vasculitis (AAV). Front Med (Lausanne). 2021;8: 783757. https://doi.org/10.3389/fmed.2021.783757. (PubMed PMID: 35127750).CrossRefPubMed

33.

Murosaki T, Sato T, Akiyama Y, Nagatani K, Minota S. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol. 2017. https://doi.org/10.1080/14397595.2016.1192760. (PubMed PMID: 27320904).CrossRefPubMed

34.

Haroun MK, Stone JH, Nair R, Racusen L, Hellmann DB, Eustace JA. Correlation of percentage of normal glomeruli with renal outcome in Wegener’s granulomatosis. Am J Nephrol. 2002;22(5–6):497–503 (PubMed PMID: 12381950).CrossRefPubMed

35.

Boud’hors C, Copin MC, Wacrenier S, Piccoli GB, Croue A, Augusto J-F, et al. Histopathological prognostic factors in ANCA-associated glomerulonephritis. Autoimmun Rev. 2022;21(9): 103139. https://doi.org/10.1016/j.autrev.2022.103139. (PubMed PMID: 35835443).CrossRefPubMed

36.

Chen A, Lee K, D’Agati VD, Wei C, Fu J, Guan T-J, et al. Bowman’s capsule provides a protective niche for podocytes from cytotoxic CD8+ T cells. J Clin Invest. 2018;128(8):3413–24. https://doi.org/10.1172/JCI97879. (PubMed PMID: 29985168).CrossRefPubMedPubMedCentral

37.

Apel F, Zychlinsky A, Kenny EF. The role of neutrophil extracellular traps in rheumatic diseases. Nat Rev Rheumatol. 2018;14(8):467–75. https://doi.org/10.1038/s41584-018-0039-z. (PubMed PMID: 29930301).CrossRefPubMed

38.

Kumar SVR, Kulkarni OP, Mulay SR, Darisipudi MN, Romoli S, Thomasova D, et al. Neutrophil extracellular trap-related extracellular histones cause vascular necrosis in severe GN. J Am Soc Nephrol. 2015;26(10):2399–413. https://doi.org/10.1681/ASN.2014070673. (PubMed PMID: 25644111).CrossRefPubMedPubMedCentral

39.

van Dam LS, Rabelink TJ, van Kooten C, Teng YKO. Clinical implications of excessive neutrophil extracellular trap formation in renal autoimmune diseases. Kidney Int Rep. 2019;4(2):196–211. https://doi.org/10.1016/j.ekir.2018.11.005. (PubMed PMID: 30775617).CrossRefPubMed

40.

Flint SM, McKinney EF, Smith KGC. Emerging concepts in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Rheumatol. 2015;27(2):197–203. https://doi.org/10.1097/BOR.0000000000000145. (PubMed PMID: 25629443).CrossRefPubMed

41.

Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011. https://doi.org/10.1126/scitranslmed.3001180. (PubMed PMID: 21389263).CrossRefPubMedPubMedCentral

42.

Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood. 2012;120(15):3007–18. https://doi.org/10.1182/blood-2012-03-416156. (PubMed PMID: 22932797).CrossRefPubMed

43.

Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87(11):4115–9 (PubMed PMID: 2161532; PubMed Central PMCID: PMCQ1).CrossRefPubMedPubMedCentral

44.

Franssen CF, Huitema MG, Muller Kobold AC, Oost-Kort WW, Limburg PC, Tiebosch A, et al. In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. J Am Soc Nephrol. 1999;10(7):1506–15 (PubMed PMID: 10405206; PubMed Central PMCID: PMCQ1).CrossRefPubMed

45.

Espy C, Morelle W, Kavian N, Grange P, Goulvestre C, Viallon V, et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener’s). Arthritis Rheum. 2011;63(7):2105–15. https://doi.org/10.1002/art.30362. (PubMed PMID: 21437874).CrossRefPubMed

46.

Damoiseaux J. ANCA testing in clinical practice: from implementation to quality control and harmonization. Front Immunol. 2021;12: 656796. https://doi.org/10.3389/fimmu.2021.656796. (PubMed PMID: 33796118).CrossRefPubMedPubMedCentral

47.

Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis–a meta-analysis. Rheumatology (Oxford). 2012;51(1):100–9. https://doi.org/10.1093/rheumatology/ker280. (PubMed PMID: 22039267).CrossRefPubMed

Titel: Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA
verfasst von: Yizi Gong
Chanjuan Shen
Ting Meng
Wei Lin
Xueling Hu
Rong Tang
Qi Xiong
Joshua D. Ooi
Peter J. Eggenhuizen
Jinbiao Chen
Ya-Ou Zhou
Hui Luo
Jia Xu
Ning Liu
Ping Xiao
Xiangcheng Xiao
Yong Zhong
Publikationsdatum: 01.12.2024
Verlag: Springer International Publishing
Erschienen in: Clinical and Experimental Medicine / Ausgabe 1/2024
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-024-01318-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA

Abstract

Publisher's Note

Introduction